Lv Keepall 55
to apply rHuPH20 to three additional targets through the payment of annual license maintenance fees. Lv Wristlet
The European approval was primarily based on data from the pivotal SABRINA study, which was Lv Keepall 55 recently published in the Lancet Oncology[i]. NHL represents approximately 85% of all lymphoma diagnosed[ii] and was responsible for approximately 200,000 annual deaths worldwide in 2012[iii].
Safe Harbor Statement
This release includes forward looking statements such as the potential benefits of MabThera SC to patients, physicians and the healthcare system, and the possible receipt by Halozyme of future milestones and royalties under the Halozyme Roche collaboration agreement. Halozyme does not undertake to update its forward looking statements.[i] Davies, A. et al. (2014) Pharmacokinetics and safety of subcutaneous rituximab in follicular lymphoma (SABRINA): stage 1 analysis of a randomised phase 3 study The Lancet Oncology, Early Online Publication, 10 February 2014[ii] Globocan (2012) Table by cancers. Worldwide incidence of cancers in males and females.
(NASDAQ: HALO) announced today that the European Commission (EC) has approved Roche's new subcutaneous (SC) formulation of MabThera(rituximab) for the treatment of patients with follicular lymphoma and diffuse large B cell lymphoma. Following the approval of Herceptin SC in September 2013, this is the second European approval for a novel subcutaneous formulation of one of Roche's oncology products using Halozyme's patented Enhanze (recombinant human hyaluronidase) technology.
Subject to the successful achievement of clinical, regulatory, and sales events, Roche will pay Halozyme additional milestones as well as royalties on product sales for Herceptin SC, MabThera SC and any other product candidates which would be successfully developed and commercialized under the agreement. is a biopharmaceutical company dedicated to developing and commercializing innovative products that advance patient care. With a diversified portfolio of enzymes that target the extracellular matrix, the Company's research focuses primarily on a family of human enzymes, known as hyaluronidases, which increase the dispersion and absorption of biologics, drugs and fluids. Halozyme's pipeline addresses therapeutic areas, including oncology, diabetes and dermatology that have significant unmet medical need today. The Company markets Hylenex recombinant (hyaluronidase human injection) and has partnerships with Roche, Pfizer and Baxter. Halozyme is headquartered in San Diego, CA.
organs) which helps to keep the bodily fluid levels balanced and to defend the body against invasion by disease. Lymphoma develops when white blood cells (usually B lymphocytes) in the lymph fluid become cancerous and begin to multiply and collect in the lymph nodes or lymphatic tissues such as the spleen. To date, Roche has elected to explore the use of rHuPH20 for up to a total of five exclusive targets, and Roche retains the option Lv Backpack Explorer
Lymphomas are a cancer of the lymphatic system (composed of lymph vessels, lymph nodes and Sunglasses Louis Vuitton
"Today's approval in the EU offers another treatment option for patients with common forms of non Hodgkin lymphoma and is yet another validating milestone for our proprietary technology," said Dr. Helen Torley, President and Chief Executive Officer. "With an administration time of approximately five minutes compared to the approximately 2.5 hour infusion time for intravenous MabThera, this innovative formulation could potentially save time for patients, physicians and other health care providers in Europe."
European Commission EC Approves Roches New Formulation Of Blood Cancer Dru
Lv Keepall 55
Adidas D Rose 3.5 PurpleHome
Louis Vuitton Evidence Sunglasses Price
Adidas All Stars Original
Adidas Boost Pink
Louis Vuitton Limited Edition Bags
Eva Lv Damier
Adidas Climacool 1 Womens
Wallet Lv For Women
Louis Vuitton 2017
Louis Vuitton White Purse
Adidas Climacool Feather
Louis Vuitton Neverfull Pm Size
Louis Vuitton Key Pouch Size
Lv Alma Bb
/ Lv Keepall 55